{"groups":[{"description":"Patients undergo observation.","id":"FG000","title":"GTR1 Differentiated Histology Supratentorial (Group 1)"},{"description":"Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.\n\nradiation therapy: Given once daily 5 days a week for 6-6½ weeks","id":"FG001","title":"Radiation (Group 2)"},{"description":"Patients receive initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.\n\nfilgrastim: Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \\>1500/μl given subcutaneously or intravenously.\n\ncarboplatin: Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patient","id":"FG002","title":"Sub-Total Resection Any Histology or Location (STR) (Group 3)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"9"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"14"}],"type":"Ineligible for study"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"}],"type":"Entry into another COG therapeutic study"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"5"}],"type":"Neuraxis dissemination during/after ther"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"287"},{"groupId":"FG002","numSubjects":"78"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"219"},{"groupId":"FG002","numSubjects":"41"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"68"},{"groupId":"FG002","numSubjects":"37"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}